Plain language summary of the mechanisms behind epilepsy in Alzheimer’s disease and the use of perampanel

Plain Language SummaryWhat is this summary about?This plain language summary summarizes the main findings from a recently published review article on epilepsy coexisting with Alzheimer’s disease (AD). The authors reviewed previously published studies because there is limited guidance on the diagnosis and treatment of epilepsy in people with AD and limited evidence to guide the choice of anti-seizure medications. The review summarized current knowledge about the relationship between AD, epilepsy, and AMPA receptors and explored whether perampanel, a medicine that blocks AMPA receptors, could be a potential treatment option.Why is it difficult to treat epilepsy in people with AD?Treating epilepsy in people with AD can be challenging. Some seizures may be difficult to recognize because they can be mistaken for changes caused by dementia. Many patients with AD are older and may have other health conditions or take several medicines, so doctors need to choose epilepsy medicines carefully. There are currently no treatment guidelines specifically for people with both AD and epilepsy.What are the key takeaways?AD and epilepsy can worsen each other. AMPA receptors, which help brain cells communicate, may play a role in this process. When these receptors become overactive, they can increase the risk of seizures. Perampanel blocks AMPA receptors and may help reduce seizures by calming excessive activity in the brain.